title: Crossing paths in Human Renal Cell Carcinoma (hRCC).
abstract: Historically, cell-signaling pathways have been studied as the compilation of isolated elements into a unique cascade that transmits extracellular stimuli to the tumor cell nucleus. Today, growing evidence supports the fact that intracellular drivers of tumor progression do not flow in a single linear pathway, but disseminate into multiple intracellular pathways. An improved understanding of the complexity of cancer depends on the elucidation of the underlying regulatory networks at the cellular and intercellular levels and in their temporal dimension. The high complexity of the intracellular cascades causes the complete inhibition of the growth of one tumor cell to be very unlikely, except in cases in which the so-called &ldquo;oncogene addiction&rdquo; is known to be a clear trigger for tumor catastrophe, such as in the case of gastrointestinal stromal tumors or chronic myeloid leukemia. In other words, the separation and isolation of the driver from the passengers is required to improve accuracy in cancer treatment. This review will summarize the signaling pathway crossroads that govern renal cell carcinoma proliferation and the emerging understanding of how these pathways facilitate tumor escape. We outline the available evidence supporting the putative links between different signaling pathways and how they may influence tumor proliferation, differentiation, apoptosis, angiogenesis, metabolism and invasiveness. The conclusion is that tumor cells may generate their own crossroads/crosstalk among signaling pathways, thereby reducing their dependence on stimulation of their physiologic pathways.
authors.affiliation: Biomedical Research Institute (INIBIC), CHU A Coruña, Xubias de Abaixo s/n, PC 15006,  A Coruña, Spain. vanessa.medina.villaamil@sergas.es.
authors.forename: Guadalupe Aparicio
authors.initials: GA
authors.lastname: Gallego
authors.forename: Vanessa Medina
authors.initials: VM
authors.lastname: Villaamil
authors.forename: Enrique
authors.initials: E
authors.lastname: Grande
authors.forename: Isabel Santamarina
authors.initials: IS
authors.lastname: Caínzos
authors.forename: Luís M Antón
authors.initials: LM
authors.lastname: Aparicio
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D002292:Carcinoma, Renal Cell / Q000473:pathology*; D066246:ErbB Receptors / Q000378:metabolism; D006801:Humans; D051793:Hypoxia-Inducible Factor 1 / Q000378:metabolism; D007680:Kidney Neoplasms / Q000378:metabolism / Q000473:pathology*; D051880:Receptors, Notch / Q000378:metabolism; D015398:Signal Transduction; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D051793:Hypoxia-Inducible Factor 1; D051880:Receptors, Notch; D016159:Tumor Suppressor Protein p53; D042461:Vascular Endothelial Growth Factor A; D066246:ErbB Receptors